News
New jab that’s ‘cheaper than Ozempic and Mounjaro’ melts fat at double the rate of other GLP-1 drugs
A NEW drug developed to combat diabetes and obesity melts fat at double the rate of other GLP-1 drugs, scientists say. The ...
Welcome to the Money blog, Sky News' consumer and personal finance hub. Today: we take an overview of the mortgage market and ...
BRITAIN has gone fat jab crazy — with sales of Wegovy soaring by more than 2,000 per cent in the past month. Dieters are ...
Through innovation, cost discipline, legal action, and competitive pricing, Novo Nordisk has reasserted its leadership in the GLP-1 market. With a robust pipeline and global expansion, NVO is poised ...
Mounjaro and other GLP-1 drugs may lower cancer risk in obese patients, according to a new study. Read more here.
In the wake of weight-loss drugs and the rising importance of health, the iconic cultural brand must double down on its roots ...
CheqUp said it had experienced a spike in interest from consumers wanting to switch or begin taking the medication.
GLP-1 drugs for diabetes and weight loss may influence patients’ cancer risk, usually lowering it but sometimes possibly increasing it, new findings suggest.
This is all you need to know about the new weight loss jab 'Reta' that's said to be 3 times stronger than Ozempic.
Dr. Hussein Tawbi, who works for MD Anderson in Houston, said there are two things he hopes people take away from the story of Cowboys owner Jerry Jones beating cancer.
Viking Therapeutics (VKTX 5.71%) fell a whopping 39.2% from their previous close on Tuesday, Aug. 19. Investors were reacting ...
Eli Lilly and Company (NYSE: LLY) is one of the best stocks to invest in for the long term. In a report released on August 13, Seamus Fernandez from Guggenheim maintained a Buy rating on Eli Lilly and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results